ReviewAlimentary pharmacology & therapeutics2020
Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.
Review in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- The effectiveness of continuity of care in patients with inflammatory bowel disease: a systematic review.BMC gastroenterology · 2024Pooled it
- Remote care through telehealth for people with inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.Journal of Crohn's & colitis · 2020Guideline
- The impact of the COVID-19 surge after the end of China's Zero-COVID policy on the health-related quality of life of IBD patients.BMC gastroenterology · 2024Article
- SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.Przeglad gastroenterologiczny · 2024Article
- Life changes, self-prevention, knowledge and mental health among inflammatory bowel disease patients during COVID-19 pandemic: a cross-sectional study.Frontiers in public health · 2024Article
- The Factors Associated with the Development of COVID-19 Symptoms among Employees in a U.S. Healthcare Institution.International journal of environmental research and public health · 2023Article
- Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.Scientific reports · 2023Article
- Diarrhea and Coronavirus Disease 2019 Infection.Gastroenterology clinics of North America · 2023Review
- Has the COVID-19 Pandemic Worsened Health-Related Quality of Life of Patients with Inflammatory Bowel Disease? A Longitudinal Disease Activity-Controlled Study.International journal of environmental research and public health · 2023Article
- Article
- Review
- COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal.Journal of medical virology · 2022Review
- The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions.Journal of clinical medicine · 2022Review
- COVID-19 induces gastrointestinal symptoms and affects patients' prognosis.The Journal of international medical research · 2022Review
- Application and Challenges of IoT Healthcare System in COVID-19.Sensors (Basel, Switzerland) · 2022Review
- COVID-19: Current Status in Gastrointestinal, Hepatic, and Pancreatic Diseases-A Concise Review.Tropical medicine and infectious disease · 2022Review
- Article
- COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).Journal of clinical medicine · 2022Review
- Letter: association between COVID-19 and inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID-19.
aimTo summarise the scale of the COVID-19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID-19 management options and drug interactions in the IBD population.
methodsA literature review on IBD, SARS-CoV-2 and COVID-19 was undertaken and relevant literature was summarised and critically examined.
resultsIBD patients do not appear to be more susceptible to SARS-CoV-2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID-19. IBD medication adherence should be encouraged to prevent disease flare but where possible high-dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co-morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID-19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID-19 are being considered, potential drug interactions should be checked.
conclusionsIBD patient management presents a challenge in the current COVID-19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.